First National Trust Co. Reduces Stake in Eli Lilly and Company (LLY)
First National Trust Co. cut its position in Eli Lilly and Company (NYSE:LLY) by 16.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 71,795 shares of the company’s stock after selling 14,016 shares during the period. First National Trust Co.’s holdings in Eli Lilly and Company were worth $6,039,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the company. First Command Financial Services Inc. increased its position in Eli Lilly and Company by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock worth $103,000 after buying an additional 84 shares during the period. Heritage Trust Co purchased a new position in Eli Lilly and Company during the first quarter worth about $135,000. LeJeune Puetz Investment Counsel LLC purchased a new position in Eli Lilly and Company during the fourth quarter worth about $136,000. Crestwood Advisors Group LLC purchased a new position in Eli Lilly and Company during the first quarter worth about $179,000. Finally, Alpha Windward LLC increased its position in Eli Lilly and Company by 2.0% in the first quarter. Alpha Windward LLC now owns 2,251 shares of the company’s stock worth $189,000 after buying an additional 44 shares during the period. Institutional investors and hedge funds own 75.41% of the company’s stock.
Shares of Eli Lilly and Company (NYSE LLY) opened at 84.35 on Friday. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $86.72. The company has a market capitalization of $89.10 billion, a P/E ratio of 40.79 and a beta of 0.35. The company has a 50-day moving average price of $80.49 and a 200 day moving average price of $79.95.
Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, April 25th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.96 by $0.02. Eli Lilly and Company had a return on equity of 26.64% and a net margin of 10.13%. The company had revenue of $5.23 billion for the quarter, compared to analyst estimates of $5.22 billion. During the same period in the prior year, the company posted $0.83 EPS. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. On average, equities analysts anticipate that Eli Lilly and Company will post $4.12 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.47%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and Company’s dividend payout ratio is currently 100.48%.
WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/07/16/first-national-trust-co-reduces-stake-in-eli-lilly-and-company-lly.html.
LLY has been the subject of a number of research reports. Citigroup Inc. reiterated a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and Company in a report on Thursday, April 6th. Zacks Investment Research upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $94.00 price objective for the company in a report on Tuesday, April 4th. Credit Suisse Group reiterated a “buy” rating on shares of Eli Lilly and Company in a report on Tuesday, March 21st. Jefferies Group LLC reiterated a “buy” rating and issued a $97.00 price objective on shares of Eli Lilly and Company in a report on Monday, April 10th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and Company in a report on Monday, April 17th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $87.61.
In related news, SVP Enrique A. Conterno sold 25,000 shares of the company’s stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $82.76, for a total transaction of $2,069,000.00. Following the transaction, the senior vice president now directly owns 114,217 shares of the company’s stock, valued at approximately $9,452,598.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $79.97, for a total value of $1,825,955.01. Following the transaction, the vice president now directly owns 62,056 shares in the company, valued at $4,962,618.32. The disclosure for this sale can be found here. Insiders have sold a total of 474,733 shares of company stock worth $39,634,487 over the last ninety days. 0.20% of the stock is currently owned by corporate insiders.
Eli Lilly and Company Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.